DEFA14A: Black Diamond Therapeutics Sets Date for 2024 Annual Stockholders Meeting
Proxy Statement
Black Diamond Therapeutics will hold its annual stockholders meeting virtually on June 6, 2024, to vote on key proposals including the election of directors and ratification of the company's accounting firm.
Summary
- Black Diamond Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024.
- Stockholders can vote on proposals including the election of Class I Directors and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Another proposal involves amending the company's Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law.
- The voting deadline is June 5, 2024, at 11:59 PM EDT.
- Stockholders can access meeting materials and vote online at www.ProxyVote.com.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, indicating a neutral to slightly positive sentiment as it reflects routine corporate governance activities.
Positives
- The company is providing multiple avenues for stockholders to access meeting materials and vote, including online access and toll-free phone number.
- The proposals are clearly outlined, allowing stockholders to make informed decisions.
Future Outlook
The Board of Directors will consider and act upon any other business that may properly come before the upcoming 2024 annual meeting of stockholders or any adjournment or postponement thereof.
Industry Context
Proxy statements and annual meetings are standard practice for publicly traded companies to ensure shareholder participation in key decisions.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Certificate of Incorporation | Proposal to amend the Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law. | Upon approval | Aims to protect officers from certain liabilities, potentially making the company more attractive to executive talent. |
Stakeholder Impact
- Shareholders have the opportunity to vote on key decisions affecting the company's governance and direction.
- The outcome of the vote on officer liability could impact the company's ability to attract and retain executive talent.
Next Steps
- Stockholders should review the proxy materials and vote on the proposals by the June 5, 2024 deadline.
- The company will hold the Annual Meeting of Stockholders on June 6, 2024.
Key Dates
| Date | Description |
|---|---|
| May 23, 2024 | Deadline to request a paper or email copy of the meeting materials. |
| June 5, 2024 | Voting deadline at 11:59 PM EDT. |
| June 6, 2024 | Annual Meeting of Stockholders at 9:00 AM Eastern Time. |
| December 31, 2024 | End of the fiscal year for which PricewaterhouseCoopers LLP's appointment is being ratified. |
Keywords
Annual Meeting, Stockholders, Proxy Vote, Black Diamond Therapeutics, Directors, PricewaterhouseCoopers, Officer Liability, Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.